Form 4: Director Corsee Sanders Receives Ultragenyx Equity Grant

Director Corsee Sanders was granted 7,751 restricted stock units and 14,058 stock options as part of the company's 2023 Incentive Plan.

Summary

• Director Corsee Sanders acquired 7,751 restricted stock units (RSUs) on May 14, 2026.
• Director Corsee Sanders was granted 14,058 stock options with an exercise price of $25.80.
• Both the RSUs and stock options vest on the earlier of the next Annual Meeting of Stockholders or May 14, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Issuance of equity results in minor dilution to existing shareholders.

Risks

• Potential for future dilution if stock options are exercised.

Future Outlook

The equity awards are subject to vesting conditions tied to the next Annual Meeting of Stockholders or May 14, 2027.

Management Comments

• The awards were granted under the Company's 2023 Incentive Plan.

Industry Context

StockSavvy.ai notes that standard equity compensation for board members is a common practice in the biotechnology sector to ensure director retention and alignment with corporate performance.

Comparison to Industry Standards

• Equity grants to directors are consistent with standard corporate governance practices for mid-cap pharmaceutical companies.
• Vesting schedules of one year are typical for annual director equity refreshers.

Corporate Governance

Stakeholder Impact

• Minor dilution for shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity awards on the earlier of the next Annual Meeting of Stockholders or May 14, 2027.

Key Dates

Keywords

Ultragenyx, RARE, Form 4, Insider Trading, Equity Compensation, Director Compensation